Teva sales increase by 2%

JERUSALEM — Teva Pharmaceutical Industries had $5.1 billion in sales and $711 million in profits in third-quarter 2013, the Israeli drug maker said.

Sales for the quarter represented a 2% increase in sales over third quarter 2012 and included $2.7 billion in U.S. sales, a 4% increase over one year ago; the company had a $79 million loss in third quarter 2012. In the United States, nearly $1.14 billion in sales came from generic drugs, up from $1.07 billion in second quarter 2012, while $1.5 billion came from the company's specialty division, which includes its branded drugs business.

Copaxone (glatiramer acetate), an injected drug used to treat multiple sclerosis, had sales of $1.05 billion, a 1% increase over third quarter 2012, while the cancer drug Treanda (bendamustine) had sales of $184 million, a 15% increase over last year, and Teva Women's Health had sales of $126 million, a 31% increase.